Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need

Content Format:

Slideset

Credit Type:

--

Credits:

--
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Content Format:

Podcast Episodes

Credit Type:

ABIM MOC | AMA

Credits:

0.75
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Content Format:

Video

Credit Type:

ABIM MOC | AMA

Credits:

1.50
The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents

Content Format:

Slideset

Credit Type:

ABIM MOC | AMA

Credits:

0.75